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the focus of this study, are key pieces of information nec-
essary for decision-makers in evaluating economic out-
comes study ﬁndings. This analysis suggests the need for
continued emphasis of guidelines calling for clear identi-
ﬁcation of the source and perspective of cost data.
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OBJECTIVES: Using (SG) or time tradeoff (TTO) mea-
sures of QALY utility weights requires strong and gener-
ally unrealistic assumptions that effectively break the link
between SG and TTO utilities and utility-theoretic pref-
erences. In particular, QALY linearity assumptions violate
the generally accepted law of diminishing marginal utility.
This presentation derives general “super QALYs” from
nonlinear, ordinal utility functions that incorporate
wealth and non-health utility variables as well as time in
speciﬁc health states. Thus super QALYs can incorporate
patient satisfaction related to dosage or drug administra-
tion and other utility-relevant factors for both acute and
chronic health outcomes. METHODS: We illustrate com-
parisons between conventional QALY and super QALY
measures using linear and Cobb-Douglas utility func-
tions. Under general conditions, nonlinear super QALYs
may rank health outcomes differently than QALYs, but
linear super QALYs rank outcomes similarly. If prefer-
ences are nonlinear, marginal changes will be weighted
differently with QALYs and super QALYs, thus affecting
incremental cost-effectiveness ratios. When derived from
consistent utility-theoretic preference relations, super
QALYs, willingness to pay (WTP), and willingness to wait
(WTW) represent alternative and equivalent rescaling of
the same preference information. RESULTS: We explore
the empirical signiﬁcance of these conceptual results using
an empirical utility function from a recent choice-format
conjoint study of acute respiratory and cardio-vascular
symptoms. Setting utility to zero for the worst-observed
outcome, quality-adjusted life days (QALDs) range from
0.066 for 5 days of pneumonia symptoms requiring hos-
pitalization to 4.25 for 5 days of nasal congestion with
some physical activity restrictions. Corresponding WTP,
WTP per QALD, and WTW values for the same outcomes
are $980 and $30, $199 and $40, and 4.93 and 0.75,
respectively. CONCLUSIONS: Although nonlinear
ordinal utility functions sacriﬁce the simplicity of con-
stant QALY weights and linearity over time, improved
validity justiﬁes the modest increase in analytical burden
in many cases.
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OBJECTIVES: International pharmacoeconomic studies
should comply with methodological guidelines, which
state that cost data must be country-speciﬁc and clearly
referenced. This study aims to identify the different
requirements in each country and report costing sources
that can be used. It also establishes common requirements
between countries, and identiﬁcation and data type issues
in each country. METHOD: Seven European countries
were chosen for analysis. Literature was analysed to
review current pharmacoeconomic guidelines, costing
requirements and perspective that should be adopted.
Using the review results, and researchers with pharma-
coeconomic expertise and local country knowledge, rele-
vant country costing sources were found. Each source was
reviewed and data extracted into an international costing
sources database. Particular attention was given to the
reliability of the source, price year, frequency of updates,
type and level of costing, allowing meaningful compar-
isons between countries. RESULTS: Even though an
important issue in international economic studies is cross-
country cost analyses, there was very little published lit-
erature showing combined synthesis of costing sources.
International guidelines tended to recommend the use of
direct costs, particularly from the perspective of the gov-
ernment or third party payer. Main internationally re-
cognised medical direct costs include medical visits,
pharmaceuticals and hospitalisations, but between coun-
tries, the costing units may differ. The level of costing
varied among countries and several reported hospitalisa-
tions costs are at DRG (Diagnosis Related Group) or spe-
cialty levels, for example. The frequency of price updates
was not similar among countries, generally from one to
three years. CONCLUSION: The database was popu-
lated following pharmacoeconomic guidelines, ensuring
relevance, accuracy and quality of cost data collection.
These factors are essential in conducting economic eval-
uations. This summarising of data allows an easy way of
identifying what is available in each country and what
methods should be adopted when performing pharma-
coeconomic cost analyses. With research sponsors often
looking towards international economic models and
analyses, such timely information is important.
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Health care decision makers often have to make their
decisions quickly and using information that is less than
perfect. The provision of information is challenging as
short timescales preclude primary data collection. As a
result reliance is place on modelling exercises informed
by systematic review. OBJECTIVE: Using value of infor-
mation techniques may help to quantify the extent of
uncertainty and identify whether it is cost-effective to
gather more information. Uncertainty in modelling is out-
lined here in the frame of the rapid assessment of the cost-
effectiveness of home haemodialysis for end stage renal
failure (ESRF). METHODS: A net beneﬁt approach is
adopted to compute value of gathering more information.
Evaluation was hampered as data on the costs and rela-
tive effectiveness of ESRF treatments are limited. The
short time frame available for the study caused further
uncertainty, resulting in two treatment options being
treated as absorbing states (as was death) in the Markov
model. Generalisable data were also limited. For example,
cost data, although detailed and comprehensive, related
to one centre and no utility data were available for the
setting of interest. Such challenges were overcome by 
discussing the framing of the research question with the
decision-maker and undertaking thorough sensitivity
analysis. RESULTS: An initial deterministic model pro-
vided sufﬁcient information for decision. A subsequent
probabilistic analysis broadly supported the decision
(although its results were unavailable at the time to deci-
sion-makers). The initial decision did not explicitly con-
sider the value of improvements to the evidence base
although this was facilitated by the probabilistic analysis.
CONCLUSON: Value of information analysis can help
to measure uncertainty surrounding results based on
imperfect information and may become a useful addition
both to those undertaking economic evaluations and deci-
sion makers themselves.
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OBJECTIVES: To present a protocol of a medicoeco-
nomic study which compares—in terms of medical effec-
tiveness, satisfaction and costs—outpatient management
of infantile bronchiolitis by paediatricians vs homeo-
pathic and allopathic GPs in France. METHODS: We
performed a bibliographic review and consulted clinical,
statistical, and health-economics experts to deﬁne and
validate the protocol. RESULTS: A prospective, “real-
world”, observational study is to be carried out. Two
independent epidemiological/economic observatories are
to be set up with 130GPs and 80 paediatricians recruited
by sample-drawing. Each doctor is to include 4 “patients
aged between 3 and 24-months, consulting for their ﬁrst
bout of acute bronchiolitis since birth, who have not yet
received treatment and who do not require immediate
hospitalisation”. The patients are to be monitored for a
period of 6 months. The diagnostic criteria are: dry cough
and/or tachypnea and/or intercostal retraction and/or
wheezing. Throughout the entire monitoring period,
medical effectiveness is to be assessed in terms of: 1)
number, severity and duration of bouts; 2) complications;
and 3) persistence of bronchial obstruction. Parent and
doctor satisfaction is to be assessed using a 4-level Likert
